New Observation on Androgen Action: Androgen Receptor Stabilization and Antisteroid Effects of LHRH Agonists

Author(s):  
W. Wright ◽  
K. Chan ◽  
K. Sundaram ◽  
C. W. Bardin
2002 ◽  
Vol 20 (6) ◽  
pp. 326-330 ◽  
Author(s):  
Takashi Sato ◽  
Hirotaka Kawano ◽  
Shigeaki Kato

2011 ◽  
Vol 32 (6) ◽  
pp. 711-717 ◽  
Author(s):  
P. Sipila ◽  
A. Krutskikh ◽  
D. A. Pujianto ◽  
M. Poutanen ◽  
I. Huhtaniemi

2009 ◽  
Vol 94 (1) ◽  
pp. 277-284 ◽  
Author(s):  
Ilpo T. Huhtaniemi ◽  
Stephen R. Pye ◽  
Kate L. Limer ◽  
Wendy Thomson ◽  
Terence W. O'Neill ◽  
...  

2014 ◽  
Vol 21 (4) ◽  
pp. T105-T118 ◽  
Author(s):  
Christine Helsen ◽  
Thomas Van den Broeck ◽  
Arnout Voet ◽  
Stefan Prekovic ◽  
Hendrik Van Poppel ◽  
...  

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.


The Prostate ◽  
2004 ◽  
Vol 62 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Dacheng Ding ◽  
Lihua Xu ◽  
Mani Menon ◽  
G. Prem Veer Reddy ◽  
Evelyn R. Barrack

2015 ◽  
Vol 11 (12) ◽  
pp. 3347-3354 ◽  
Author(s):  
Hongli Liu ◽  
Xiaoli An ◽  
Shuyan Li ◽  
Yuwei Wang ◽  
Jiazhong Li ◽  
...  

R-Bicalutamide is a first generation antiandrogen used to treat prostate cancer, which inhibits androgen action by competitively binding to the androgen receptor (AR).


Endocrinology ◽  
2005 ◽  
Vol 146 (9) ◽  
pp. 4117-4126 ◽  
Author(s):  
Karel De Gendt ◽  
Nina Atanassova ◽  
Karen A. L. Tan ◽  
Luiz Renato de França ◽  
Gleydes Gambogi Parreira ◽  
...  

Abstract It is established that androgens and unidentified Sertoli cell (SC)-derived factors can influence the development of adult Leydig cells (LC) in rodents, but the mechanisms are unclear. We evaluated adult LC development and function in SC-selective androgen receptor (AR) knockout (SCARKO) and complete AR knockout (ARKO) mice. In controls, LC number increased 26-fold and LC size increased by approximately 2-fold between 12 and 140 d of age. LC number in SCARKOs was normal on d 12, but was reduced by more than 40% at later ages, although LC were larger and contained more lipid droplets and mitochondria than control LC by adulthood. ARKO LC number was reduced by up to 83% at all ages compared with controls, and LC size did not increase beyond d 12. Serum LH and testosterone levels and seminal vesicle weights were comparable in adult SCARKOs and controls, whereas LH levels were elevated 8-fold in ARKOs, although testosterone levels appeared normal. Immunohistochemistry and quantitative PCR for LC-specific markers indicated steroidogenic function per LC was probably increased in SCARKOs and reduced in ARKOs. In SCARKOs, insulin-like factor-3 and estrogen sulfotransferase (EST) mRNA expression were unchanged and increased 3-fold, respectively, compared with controls, whereas the expression of both was reduced more than 90% in ARKOs. Changes in EST expression, coupled with reduced platelet-derived growth factor-A expression, are potential causes of altered LC number and function in SCARKOs. These results show that loss of androgen action on SC has major consequences for LC development, and this could be mediated indirectly via platelet-derived growth factor-A and/or estrogens/EST.


2011 ◽  
Vol 25 (2) ◽  
pp. 269-281 ◽  
Author(s):  
Eui-Ju Hong ◽  
Biswajyoti Sahu ◽  
Olli A. Jänne ◽  
Geoffrey L. Hammond

Abstract Human sex hormone-binding globulin (SHBG) accumulates within the cytoplasm of epithelial cells lining the proximal convoluted tubules of mice expressing human SHBG transgenes. The main ligands of SHBG, testosterone and its metabolite, 5α-dihydrotestosterone (DHT), alter expression of androgen-responsive genes in the kidney. To determine how intracellular SHBG might influence androgen action, we used a mouse proximal convoluted tubule (PCT) cell line with characteristics of S1/S2 epithelial cells in which human SHBG accumulates. Western blotting revealed that SHBG extracted from PCT cells expressing a human SHBG cDNA (PCT-SHBG) is 5–8 kDa smaller than the SHBG secreted by these cells, due to incomplete N-glycosylation and absence of O-linked oligosaccharides. PCT-SHBG cells sequester [3H]DHT more effectively from culture medium than parental PCT cells, and the presence of SHBG accentuates androgen-dependent activation of a luciferase reporter gene, as well as the endogenous kidney androgen-regulated protein (Kap) gene. After androgen withdrawal, androgen-induced Kap mRNA levels in PCT-SHBG cells are maintained for more than 2 wk vs 2 d in parental PCT cells. Transcriptome profiling after testosterone or DHT pretreatments, followed by 3 d of steroid withdrawal, also demonstrated that intracellular SHBG enhances androgen-dependent stimulation (e.g.Adh7, Vcam1, Areg, Tnfaip2) or repression (e.g.Cldn2 and Osr2) of many other genes in PCT cells. In addition, nuclear localization of the androgen receptor is enhanced and retained longer after steroid withdrawal in PCT cells containing functional SHBG. Thus, intracellular SHBG accentuates the uptake of androgens and sustains androgens access to the androgen receptor, especially under conditions of limited androgen supply.


2014 ◽  
Vol 21 (4) ◽  
pp. T147-T160 ◽  
Author(s):  
Cera M Nieto ◽  
Leah C Rider ◽  
Scott D Cramer

Androgen receptor (AR) signaling is vital to the development and function of the prostate and is a key pathway in prostate cancer. AR is differentially expressed in the stroma and epithelium, with both paracrine and autocrine control throughout the prostate. Stromal–epithelial interactions within the prostate are commonly dependent on AR signaling and expression. Alterations in these pathways can promote tumorigenesis. AR is also expressed in normal and malignant mammary tissues. Emerging data indicate a role for AR in certain subtypes of breast cancer that has the potential to be exploited therapeutically. The aim of this review is to highlight the importance of these interactions in normal development and tumorigenesis, with a focus on the prostate and breast.


Sign in / Sign up

Export Citation Format

Share Document